Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it compare to its competitors? We will compare Better Therapeutics to related businesses based on the strength of its risk, dividends, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Health services” companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all “Health services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Better Therapeutics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Better Therapeutics||$10,000.00||-$40.33 million||-0.72|
|Better Therapeutics Competitors||$1.36 billion||-$98.47 million||29.16|
Risk & Volatility
Better Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Better Therapeutics’ competitors have a beta of 1.48, suggesting that their average share price is 48% more volatile than the S&P 500.
This table compares Better Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Better Therapeutics Competitors||-325.87%||-481.74%||-38.64%|
This is a summary of recent ratings and target prices for Better Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Better Therapeutics Competitors||7||130||274||0||2.65|
Better Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 865.52%. As a group, “Health services” companies have a potential upside of 112.07%. Given Better Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Better Therapeutics is more favorable than its competitors.
Better Therapeutics beats its competitors on 7 of the 12 factors compared.
About Better Therapeutics
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.